Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study

Ann Intern Med. 2022 Dec;175(12):1771-1774. doi: 10.7326/M22-2089. Epub 2022 Oct 25.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2019-nCoV Vaccine mRNA-1273*
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Humans
  • Influenza Vaccines*
  • Vaccination

Substances

  • 2019-nCoV Vaccine mRNA-1273
  • Antibodies, Viral
  • Antibodies, Neutralizing
  • Influenza Vaccines